Contact

The iPSC-first CDMO 

Making cell therapies mainstream.

From cell line development to GMP manufacturing, we help bring iPSC-derived cell therapy and regenerative medicine to clinic and scale.

Scientist on cell lab

Flexible CDMO services for iPSC-Derived Cell Therapy and Regenerative Medicine programs

Cellistic supports innovators through flexible entry points across the iPSC-derived therapy journey, combining a full spectrum of CDMO services with pre-established platforms for cell line development and GMP manufacturing — Pulse™ and Echo™ — to help translate advanced programs into scalable production.

 

For immune cell therapy developers

Moving beyond autologous or donor-derived approaches? We help establish the iPSC foundation, differentiation process, and platform-enabled workflow needed to advance scalable allogeneic cell therapy.

For iPSC cell therapy and regenerative medicine programs

Already advancing an iPSC-derived program? We help translate promising therapies into GMP-ready, scalable manufacturing processes — from process development through release testing.

CDMO_schema
Artboard 1 1

Talk to the iPSC-first CDMO.

See how Cellistic can remove the scientific, operational, and economic barriers to scalable patient delivery. 

Artboard 1 1

The CDMO that can take your cell therapy mainstream.

Cellistic integrates the services, platforms, and expertise required to enable successful iPSC-derived allogeneic cell therapy GMP manufacturing – and we’re continually expanding our capabilities with a single purpose in mind: to help you limit risk, accelerate time to clinic, and reduce costs.


Puzzle Icon

Technology Platforms

  • Pulse™ Cell Line Development Platform powered by proprietary STAR-CRISPR™ gene editing and Allo Chassis™ edited cell lines
  • Cellistic Echo™ Platform for scalable GMP manufacturing
Vials Icon

CDMO  Services

Integrated support from iPSC cell line development through process and analytical development, GMP manufacturing, QC testing, and release.

Lightbulb Icon - Pink

Cell Therapy Applications

Our iPSC development, differentiation, and manufacturing capabilities support a broad range of immune and regenerative cell therapy programs.

We are here: The point of Cellistic’s difference.

A truly integrated iPSC solution provider from development to GMP

Working_Icons-2

Focus & Expertise

15+ years of exclusive iPSC focus, building deeper expertise for stronger execution

Turn the promise of your program into a reality.

Whether you’re pursuing an autologous cell therapy or already have an iPSC-based project underway, Cellistic offers a practical and proven path forward for your cell therapy or regenerative medicine — making it possible to turn a high-potential idea into a viable therapeutic faster and more efficiently.

Group 35264
iPSC-Derived Allogeneic Autologous Donor-Derived Allogeneic
Your opportunity

Transfer an existing process to a flexible, full-scale, iPSC-focused CDMO

Go from one-to-one to one-to-many using our proven platforms

Overcome limitations to increase scale, consistency, quality, and characterization

Purpose-built to deliver on iPSC potential.

Our headquarters in Mont-Saint-Guibert, Belgium, is home to the first EMA-certified and FDA and PMDA compliant purpose-built iPSC cell therapy GMP manufacturing facility.

With all capabilities in a single location, our clients collaborate closely with our multidisciplinary team, with everyone aligned on the shared goal: developing and manufacturing iPSC-based allogeneic cell therapies as efficiently and cost-effectively as possible.

lab-collection

How can we help propel your cell therapy?

Let’s start with what’s on your mind – your project plans, your questions about iPSC technology, your most pressing scientific and business drivers. We’re here to listen and, if we’re a good fit, to help you maximize the opportunity and value of your cell therapy.